Nammi Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2018-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.nammirx.com
Clinical Trials
1
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (100.0%)Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Phase 1
Recruiting
- Conditions
- Ovarian CancerPancreas CancerUrothelial CarcinomaRenal Cell CarcinomaHepatocellular CarcinomaGastrointestinal CancerLung CancerProstate CancerBreast Cancer
- First Posted Date
- 2024-09-03
- Last Posted Date
- 2024-09-03
- Lead Sponsor
- Nammi Therapeutics Inc
- Target Recruit Count
- 100
- Registration Number
- NCT06582017
- Locations
- 🇺🇸
University of Southern California, Los Angeles, California, United States
🇺🇸Cedars-Sanai Medical Center - Samuel Oschin Comprehensive Cancer, Los Angeles, California, United States
🇺🇸Hoag Memorial Hospital Presbyterian, Newport, California, United States
News
No news found